FDA Lifts Partial Clinical Hold on Key Cancer Drug Lorigerlimab's LINNET Study

summarizeSummary

MacroGenics announced the FDA has removed the partial clinical hold on its Phase 2 LINNET study for lorigerlimab, allowing enrollment to resume for the gynecologic cancer treatment.

check_boxKey Events

• Clinical Hold Removed

  The U.S. Food and Drug Administration (FDA) has removed the partial clinical hold on the Phase 2 LINNET study of lorigerlimab, an investigational bispecific DART® molecule for gynecologic cancers.

• Enrollment to Resume

  The removal of the hold allows MacroGenics to resume enrollment of new study participants in the ongoing LINNET study.

• Revised Protocol Implemented

  New participants will be enrolled under a revised protocol that includes additional risk-mitigation measures for potential hematologic and cardiac toxicities.

• Mid-Year Update On Track

  The company remains on track to provide a mid-year clinical update on the lorigerlimab program.

auto_awesomeAnalysis

This 8-K reports a critical positive development for MacroGenics, as the FDA has lifted the partial clinical hold on its Phase 2 LINNET study for lorigerlimab. This resolution removes a significant regulatory overhang that was previously noted in the company's recent 10-K filing, which mentioned the hold as a challenge. The ability to resume enrollment in this mid-stage trial for a bispecific DART® molecule targeting PD-1 and CTLA-4 is crucial for advancing a key pipeline candidate for gynecologic cancers. This de-risking event allows the company to progress towards a mid-year clinical update, and comes as the stock is trading near its 52-week high, potentially reinforcing positive investor sentiment.